Calliditas Therapeutics IPO Presentation Deck
Opportunity for disease modifying treatment of autoimmune liver
diseases
Autoimmune liver diseases originate from the liver
The autoimmune process is believed to be initiated by antigen-induced production of cytotoxic T-cells and B-
cell derived auto-antibodies.
In PBC, the cytotoxic T-cells and the auto-antibodies are directed towards antigens on the surface of the
epithelial cells of the small bile ducts in the liver, resulting in inflammation and damage to the duct cells and
eventually destroying the bile ducts¹.
• The destruction of bile ducts result in an increase of bile to levels that are toxic to the liver cells, eventually
resulting in liver impairment, cirrhosis and ESLD
In AIH, the cytotoxic T-cells and auto-antibodies are directed towards antigens presented on the surface of the
liver cells, leading to liver impairment, cirrhosis and eventually ESLD²
Source: 1) Hirshfield, 2013, Annu Rev Pathol, 8:303-30 2) Monns, Journal of Hepatology 2015, 62.5100 5111
calliditas
June 2020
27View entire presentation